Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of RHB-104 versus placebo in moderately active Crohn's disease
2014-004108-31Phase 3Terminated
- Sponsor
- RedHill Biopharma
- Start
- Apr 2015
- Modality
- Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of clarithromycin, rifabutin and clofazimine in Crohn's disease (2 arms), sponsored by RedHill Biopharma. Primary endpoint: Remission. Started Apr 2015; status: terminated.
02
Drugs
clarithromycinrifabutinclofazimine
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2014-004108-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004108-31.